Linda S Cook1, Andy C Y Leung2, Kenneth Swenerton3, Richard P Gallagher4, Anthony Magliocco5, Helen Steed6, Martin Koebel7, Jill Nation8, Sima Eshragh9, Angela Brooks-Wilson10, Nhu D Le11. 1. Internal Medicine, University of New Mexico and UNM Comprehensive Cancer Center, Albuquerque, NM, USA; Community Health Sciences, University of Calgary, Calgary, AB, Canada; Alberta Health Services, Calgary, AB, Canada. Electronic address: lcook@salud.unm.edu. 2. Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada. Electronic address: acyleung@bccrc.ca. 3. Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada. Electronic address: KSwener@bccancer.bc.ca. 4. Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada. Electronic address: rgallagher@bccrc.ca. 5. Department of Anatomic Pathology, H Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Anthony.Magliocco@moffitt.org. 6. Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada. Electronic address: Helen.Steed@albertahealthservices.ca. 7. Pathology & Laboratory Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: Martin.Koebel@cls.ab.ca. 8. Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: Jill.Nation@albertahealthservices.ca. 9. Pathology, Vancouver General Hospital, Vancouver, BC, Canada. Electronic address: sieshragh@gmail.com. 10. Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada. Electronic address: abrooks-wilson@bcgsc.ca. 11. Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada. Electronic address: nle@bccrc.ca.
Abstract
OBJECTIVE: Meta-analyses report a null association between recent alcohol consumption and ovarian cancer risk. However, because few studies investigated different types of alcohol over adult ages, we investigated adult lifetime and type (beer, wine, spirits) of consumption and risk. METHODS: Consumption after age 20years was ascertained in 1144 invasive epithelial ovarian cancer cases and 2513 controls in a population-based case-control study (Alberta and British Columbia, Canada, 2001-2012). Non-drinkers consumed any types of alcohol <12 times per year on average. Logistic regression was use to estimate adjusted odds ratios [aOR] and 95% confidence intervals [CIs]. RESULTS: Wine consumption was associated with a risk reduction (aOR=0.67, 95% CI: 0.50-0.88) relative to non-drinkers, but not beer (aOR=1.06, 95% CI: 0.71-1.58) or spirits (aOR=0.98, 95% CI: 0.69-1.39). The reduced risk was stronger for exclusive red wine drinkers (aOR=0.44, 95% CI: 0.19-0.92) than white wine drinkers (aOR=0.79, 95% CI: 0.46-1.34), although most women drank both types of wine. Risk decreased with increasing cumulative consumption of any wine (P-trend<0.05) and was evident for the serous histotype. Wine consumption initiated prior to age 50 was associated with a risk reduction (e.g., at 40-49years, aOR=0.58, 95% CI: 0.42-0.78), but not drinking initiated after 50years of age. For any type, level, or age at initiation of alcohol consumption, we found no increased risks. CONCLUSIONS: For the moderate consumption in this study, higher levels of wine consumption were generally associated with risk reductions; reductions may be stronger for red wine. Our results suggest that alcohol consumption that is guideline concordant will not increase epithelial ovarian cancer risk.
OBJECTIVE: Meta-analyses report a null association between recent alcoholconsumption and ovarian cancer risk. However, because few studies investigated different types of alcohol over adult ages, we investigated adult lifetime and type (beer, wine, spirits) of consumption and risk. METHODS: Consumption after age 20years was ascertained in 1144 invasive epithelial ovarian cancer cases and 2513 controls in a population-based case-control study (Alberta and British Columbia, Canada, 2001-2012). Non-drinkers consumed any types of alcohol <12 times per year on average. Logistic regression was use to estimate adjusted odds ratios [aOR] and 95% confidence intervals [CIs]. RESULTS: Wine consumption was associated with a risk reduction (aOR=0.67, 95% CI: 0.50-0.88) relative to non-drinkers, but not beer (aOR=1.06, 95% CI: 0.71-1.58) or spirits (aOR=0.98, 95% CI: 0.69-1.39). The reduced risk was stronger for exclusive red wine drinkers (aOR=0.44, 95% CI: 0.19-0.92) than white wine drinkers (aOR=0.79, 95% CI: 0.46-1.34), although most women drank both types of wine. Risk decreased with increasing cumulative consumption of any wine (P-trend<0.05) and was evident for the serous histotype. Wine consumption initiated prior to age 50 was associated with a risk reduction (e.g., at 40-49years, aOR=0.58, 95% CI: 0.42-0.78), but not drinking initiated after 50years of age. For any type, level, or age at initiation of alcohol consumption, we found no increased risks. CONCLUSIONS: For the moderate consumption in this study, higher levels of wine consumption were generally associated with risk reductions; reductions may be stronger for red wine. Our results suggest that alcohol consumption that is guideline concordant will not increase epithelial ovarian cancer risk.
Authors: Xin Grevers; Anne Grundy; Abbey E Poirier; Farah Khandwala; Matthew Feldman; Christine M Friedenreich; Darren R Brenner Journal: CMAJ Open Date: 2016-12-12
Authors: Martin Köbel; Li Luo; Xin Grevers; Sandra Lee; Angela Brooks-Wilson; C Blake Gilks; Nhu D Le; Linda S Cook Journal: Int J Gynecol Pathol Date: 2019-07 Impact factor: 2.762
Authors: Peter F Rambau; Robert A Vierkant; Maria P Intermaggio; Linda E Kelemen; Marc T Goodman; Esther Herpel; Paul D Pharoah; Stefan Kommoss; Mercedes Jimenez-Linan; Beth Y Karlan; Aleksandra Gentry-Maharaj; Usha Menon; Susanna Hernando Polo; Francisco J Candido Dos Reis; Jennifer Anne Doherty; Simon A Gayther; Raghwa Sharma; Melissa C Larson; Paul R Harnett; Emma Hatfield; Jurandyr M de Andrade; Gregg S Nelson; Helen Steed; Joellen M Schildkraut; Micheal E Carney; Estrid Høgdall; Alice S Whittemore; Martin Widschwendter; Catherine J Kennedy; Frances Wang; Qin Wang; Chen Wang; Sebastian M Armasu; Frances Daley; Penny Coulson; Micheal E Jones; Micheal S Anglesio; Christine Chow; Anna de Fazio; Montserrat García-Closas; Sara Y Brucker; Cezary Cybulski; Holly R Harris; Andreas D Hartkopf; Tomasz Huzarski; Allan Jensen; Jan Lubiński; Oleg Oszurek; Javier Benitez; Fady Mina; Annette Staebler; Florin Andrei Taran; Jana Pasternak; Aline Talhouk; Mary Anne Rossing; Joy Hendley; Robert P Edwards; Sian Fereday; Francesmary Modugno; Roberta B Ness; Weiva Sieh; Mona A El-Bahrawy; Stacey J Winham; Jenny Lester; Susanne K Kjaer; Jacek Gronwald; Peter Sinn; Peter A Fasching; Jenny Chang-Claude; Kirsten B Moysich; David D Bowtell; Brenda Y Hernandez; Hugh Luk; Sabine Behrens; Mitul Shah; Audrey Jung; Prafull Ghatage; Jennifer Alsop; Kathryn Alsop; Jesús García-Donas; Pamela J Thompson; Anthony J Swerdlow; Chloe Karpinskyj; Alicia Cazorla-Jiménez; María J García; Susha Deen; Lynne R Wilkens; José Palacios; Andrew Berchuck; Jennifer M Koziak; James D Brenton; Linda S Cook; Ellen L Goode; David G Huntsman; Susan J Ramus; Martin Köbel Journal: J Pathol Clin Res Date: 2018-09-21
Authors: Linda S Cook; Claire R Pestak; Andy Cy Leung; Helen Steed; Jill Nation; Kenneth Swenerton; Richard Gallagher; Anthony Magliocco; Martin Köbel; Angela Brooks-Wilson; Nhu Le Journal: Br J Cancer Date: 2016-12-13 Impact factor: 7.640
Authors: Angela My Chan; Emeka Enwere; John B McIntyre; Holly Wilson; Chidera Nwaroh; Nicholas Wiebe; Young Ou; Shuhong Liu; Katharina Wiedemeyer; Peter F Rambau; Xin Grevers; Donald G Morris; Paola Neri; C Blake Gilks; Frank Visser; Nhu Le; Li Luo; Linda S Cook; Martin Köbel Journal: J Pathol Clin Res Date: 2020-05-11